We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...
4don MSNOpinion
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
Acoramidis has been cleared under the Attruby brand name as an oral therapy to reduce cardiovascular death and cardiovascular-related hospitalisation in adults with ATTR-CM, a progressive disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback